Dexcom director receives 5,575-share RSU grant
AUGUSTINOS NICHOLAS reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
AUGUSTINOS NICHOLAS reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Nicholas Augustinos reported a new equity award and updated holdings. He received a grant of 5,575 restricted stock units (RSUs) on May 28, 2026, with each RSU representing one share of Dexcom common stock upon settlement.
The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom's 2027 Annual Meeting of Stockholders. Following this award, he holds 5,575 shares directly and 38,457 shares indirectly through the Kirschner/Augustinos Revocable Trust, where he serves as a trustee.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 5,575 shares
Grant/Award
2 txns
Insider
AUGUSTINOS NICHOLAS
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 5,575 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 5,575 shares (Direct);
Common Stock — 38,457 shares (Indirect, by Trust)
Footnotes (2)
- F1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
- F2. Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee.
Key Figures
RSU grant size: 5,575 RSUs
RSU vesting schedule: 100% cliff vest
Direct holdings after grant: 5,575 shares
+2 more
5 metrics
RSU grant size
5,575 RSUs
Granted May 28, 2026 to director Nicholas Augustinos
RSU vesting schedule
100% cliff vest
Earlier of one year from May 28, 2026 or 2027 Annual Meeting
Direct holdings after grant
5,575 shares
Dexcom common stock held directly following RSU award
Indirect trust holdings
38,457 shares
Dexcom common stock held by Kirschner/Augustinos Revocable Trust
RSU grant price
$0.00 per share
Stock-based compensation award, no cash purchase price
Key Terms
restricted stock unit (RSU), Annual Meeting of Stockholders, Revocable Trust
3 terms
restricted stock unit (RSU) financial
"Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share"
A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.
Annual Meeting of Stockholders regulatory
"will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"
Revocable Trust financial
"Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
FAQ
What insider transaction did Dexcom (DXCM) director Nicholas Augustinos report?
Nicholas Augustinos reported receiving a grant of 5,575 RSUs. The award was made on May 28, 2026, and each restricted stock unit represents a contingent right to receive one share of Dexcom common stock upon settlement, reflecting stock-based compensation rather than an open-market purchase.
How do the new RSUs granted to Dexcom (DXCM) director vest?
The 5,575 RSUs vest in a single tranche. They will vest 100% on the earlier of the one-year anniversary of the May 28, 2026 grant date or the date of Dexcom’s 2027 Annual Meeting of Stockholders, tying vesting to board service and the shareholder meeting schedule.
What is the role of the Kirschner/Augustinos Revocable Trust in Dexcom (DXCM) holdings?
The Kirschner/Augustinos Revocable Trust holds Dexcom shares for the reporting person. The Form 4 notes that 38,457 Dexcom common shares are held by this revocable trust, with Nicholas Augustinos serving as a trustee, indicating indirect ownership of those shares through the trust structure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
